MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced it will release its third-quarter 2025 financial results before the market opens on Wednesday, November 5, 2025, followed by a conference call and live webcast at 8:30 a.m. ET to discuss company performance and provide a business update.
The biotechnology firm, headquartered in Malvern, is advancing a pipeline of gene therapy programs targeting blindness and degenerative retinal diseases. Its proprietary modifier gene therapy platform takes a gene-agnostic approach, aiming to correct complex diseases that result from dysfunction across multiple gene networks rather than a single mutation.
Ocugen’s research portfolio includes potential treatments for inherited retinal diseases such as retinitis pigmentosa and Stargardt disease, as well as geographic atrophy, a severe form of dry age-related macular degeneration that affects millions worldwide.
A replay of the company’s earnings call and archived webcast will be available on Ocugen’s investor relations website for 45 days following the live event.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.